Lookup NU author(s): Dr Lei Huang,
Dr Henrique De Paula Lemos,
Professor Andrew Mellor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The term “immune privilege” was coined to describe weak immunogenicity (hypo-immunity) that manifests in some transplant settings. We extended this concept to encompass hypo-immunity that manifests at local sites of inflammation relevant to clinical diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a key metabolic process that promotes and sustains induced immune privilege, and discuss the implications for exploiting this knowledge to improve treatments for hypo-immune and hyper-immune syndromes using strategies to manipulate tryptophan metabolism.
Author(s): Li L, Huang L, Lemos HP, Mautino M, Mellor AL
Publication type: Article
Publication status: Published
Journal: Frontiers in Immunology
Online publication date: 11/05/2012
ISSN (electronic): 1664-3224
Publisher: Frontiers Research Foundation
PubMed id: 22593757
Altmetrics provided by Altmetric